SEOUL, South Korea, Dec. 17, 2025 -- Leaders Dental Laboratory, a leading force in Korea's digital dental technology sector, has announced a new vision to position itself as "the central hub of the digital dentistry ecosystem." To realize this vision, the company is making significant investments in AI-CAD, 3D printing, and IoT-based production automation. With the Korean implant market approaching saturation, Leaders Dental aims to secure long-term competitiveness by investing aggressively in next-generation technologies and expanding its reach beyond the domestic market into the g
SEOUL, South Korea, Dec. 17, 2025 -- All CONEC has signed a memorandum of understanding (MOU) with Australian digital dental company MINIMAX to establish a collaborative framework for digital implant production and lay the groundwork for overseas market entry. Digital implant production faces challenges due to differences in national product standards, production protocols, and communication methods. This partnership allows All CONEC to establish platform-based production standards at an early stage. The collaboration covers validating implant guide and prosthetic production pro
[ 메디채널 김갑성 기자 ] Orchestral – a Pioneering AI Orchestrator Data Platform Built for Healthcare AUCKLAND, New Zealand, Dec. 17, 2025 -- McCrae Tech has launched the world's first health AI orchestrator. The product, called Orchestral, is a health-native AI orchestrator data platform. It seamlessly connects diverse data sources with AI agents, workflows, and algorithms – enabling scalable, governed AI deployment across healthcare systems. "Most information technology in healthcare falls into two camps: either a big, dumb bucket of cloud data or isolated pockets of AI
Industry's highest-capacity discrete analyzer delivers true walk-away automation for commercial laboratories WESTBOROUGH, Mass., Dec. 16, 2025 -- Commercial laboratories face mounting pressure to process more samples with fewer staff while maintaining fast turnaround times. When urgent samples arrive midday, labs face an impossible choice: disrupt current analyses to accommodate rush orders, or make clients wait. Meanwhile, technicians spend hours monitoring instruments and managing complex workflows across multiple analyzers—an unsustainable approach given persistent staffing
The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with strong backing from both new investors and existing supporters Proceeds to advance two differentiated and highly competitive ADC programs in global Phase I trials The financing will support continued development of ADC and multi-specific antibody platforms aimed at addressing critical limitations of existing biologic therapeutics SHANGHAI, Dec. 16, 2025 -- Allink Biotherapeutics, Inc. (AllinkBio), a clinical-stage biotechnology company focusing on developi
BEIJING, Dec. 16, 2025 -- METiS TechBio ("METiS") today announced that two of its oncology pipeline candidates, MTS-105 and MTS-107, have been published in leading international peer-reviewed journals, Nature Communications and the Journal for ImmunoTherapy of Cancer (JITC), representing two major breakthroughs in mRNA-based cancer therapeutics. Both studies leverage METiS's proprietary AI-powered NanoForge platform, which introduces a precision-guided rocket-and-payload delivery analogy. By combining liver- and spleen-targeted lipid nanoparticle (LNP) delivery system
SAN FRANCISCO, Dec. 16, 2025 -- Biostar Pharma, Inc., the U.S. wholly-owned subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. (Stock Code: 2563.HK), today announced that the first patient has been dosed for one of its key oversea clinical studies: the U.S. pivotal clinical study (NCT06764940) of Utidelone Injection(UTD1) combined with capecitabine for the treatment of HER2-negative breast cancer brain metastases (BCBM). The study adopts a two-stage design and plans to enroll approximately 120 subjects. The primary endpoint is the central nervous system objective response rate (CN
The company secured $47 million through extension rounds of Series A led by Legend Capital and Meituan Long-Z Investment with strong backing from both new investors and existing supporters Proceeds to advance two differentiated and highly competitive ADC programs in global Phase I trials The financing will support continued development of ADC and multi-specific antibody platforms aimed at addressing critical limitations of existing biologic therapeutics SHANGHAI, Dec. 16, 2025 -- Allink Biotherapeutics, Inc. (AllinkBio), a clinical-stage biotechnology company focusing on developi
Establishment of new healthcare gateway in Chongqing amid the 10th anniversary of the Chongqing Connectivity Initiative and as part of the 35th anniversary celebration of Singapore-China diplomatic relations; Maiden investment in Chongqing marks Perennial Holdings' sixth healthcare-centric TOD, further strengthening its footprint in China SINGAPORE, Dec. 16, 2025 -- Perennial Holdings Private Limited ("Perennial Holdings") yesterday launched Perennial Healthcare City, adjacent to the Chongqing East High-Speed Railway ("HSR") Station ("Perennial
HANGZHOU, China, Dec. 16, 2025 -- Enginprime Medical Inc ("Enginprime"), an emerging leader in percutaneous ventricular assist device (pVAD) technologies and a Voyagers Capital portfolio company, today announced that its industry leading pVAD, OpusOne™, has entered its first-in-human clinical study at The Second Affiliated Hospital, School of Medicine, Zhejiang University ("SAHZU"). This milestone marks the first clinical evaluation of the device's safety and performance in patients. PVAD supports the cardiac output via a percutaneously implanted pump, reduces the l